Affimed (AFMD) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Affimed Reports Financial Results for Fourth Quarter and Year End 2015
March 30, 2016 7:30 AM EDTHEIDELBERG, Germany, March 30, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results for the fourth quarter and year ended December 31, 2015.
"2015 was a formative year for Affimed," said Dr. Adi Hoess, CEO of Affimed. "Through the continuous support of our investors we were able to broaden the development of our NK- and T-cell-recruiting immunotherapies. We have continued to successfully advance our clinical and preclinical pipeline and, in particular, we have made significant headway with our lead... More
